
    
      Main objective: Evaluation of the pharmacodynamic effect of the combination of Sildenafil and
      Riociguat on blood pressure and other safety parameters in patients with symptomatic PAH
      Secondary objectives:To investigate the safety of the riociguat/sildenafil combination and
      changes in 6-minute walk test, World Health Organization (WHO) functional class, N terminal
      pro-brain natriuretic peptide, and variables obtained during right-heart catheterization
      after 12 weeks of treatment; pharmacokinetics of riociguat and sildenafil.

      The study consists of one part. In study Part 1 only subjects (18) on stable sildenafil
      treatment of 20 mg tid have been enrolled. Study Part 2 will not start.
    
  